Transcend Therapeutics' Procysteine to enter Phase III for ARDS in early 1997 -- IPO prospectus.
Executive Summary
TRANSCEND THERAPEUTICS PROCYSTEINE TO ENTER PHASE III TRIALS for treatment of acute respiratory distress syndrome in the first quarter of 1997, the company forecasts in an Aug. 22 prospectus for an initial public offering. Procysteine treats diseases associated with oxidative damage, the prospectus states, describing it as "a system for introducing into cells the amino acid cysteine, an essential building block of glutathione," one of the body's principal mechanisms for neutralizing the highly reactive toxic molecules known as reactive oxygen species, according to Transcend.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth